NCT04576130 A Danish ICD-study in Patients with Coronary Artery Disease Resuscitated from Ventricular Fibrillation
| NCT ID | NCT04576130 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rigshospitalet, Denmark |
| Condition | Coronary Artery Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,200 participants |
| Start Date | 2020-10-12 |
| Primary Completion | 2032-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,200 participants in total. It began in 2020-10-12 with a primary completion date of 2032-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
DanICD is a randomized, controlled study to with the aim to assess whether there is a benefit of ICD-implantation in patients with coronary artery disease (including acute myocardial infarction), who survive cardiac arrest due to ventricular fibrillation/sustained ventricular tachycardia and undergo revascularization and with an LVEF above 35%.
Eligibility Criteria
Inclusion Criteria: * Patients with CAD and cardiac arrest due to VF/VT, where angiogram is performed with complete revascularization (PCI, CABG or hybrid coronary revascularization) before ICD implantation. Unfavorable artery for PCI (i.e., excessive vessel tortuosity or chronic total occlusion) or high-risk invasive treatment is not mandatory in order to achive complete revascularization. * Age ≥18 years * LVEF \>35% at the time of discharge. The most recent LVEF assessment on which the current medical treatment will be based at the time of entry into the study will be used as baseline LVEF. Exclusion Criteria: * Non-ischemic cause of cardiac arrest (i.e. ion channel diseases, non-ischemic cardiomyopathy) * Previous CABG within the last 3 months before index hospitalization * Life expectancy less than 1 year or severe neurologic outcome * Unable or unwilling to give informed consent * Pregnancy
Contact & Investigator
Reza Jabbari, MD, PhD
PRINCIPAL INVESTIGATOR
Rigshospitalet, Denmark
Frequently Asked Questions
Who can join the NCT04576130 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04576130 currently recruiting?
Yes, NCT04576130 is actively recruiting participants. Contact the research team at reza.jabbari.02@regionh.dk for enrollment information.
Where is the NCT04576130 trial being conducted?
This trial is being conducted at Copenhagen, Denmark.
Who is sponsoring the NCT04576130 clinical trial?
NCT04576130 is sponsored by Rigshospitalet, Denmark. The principal investigator is Reza Jabbari, MD, PhD at Rigshospitalet, Denmark. The trial plans to enroll 1,200 participants.